Target Validation Information
Target ID T22118
Target Name Dopamine D1 receptor
Target Type
Successful
Drug Potency against Target (R,S)-homoaromaline hydrochloride Drug Info IC50 = 15400 nM
Ro-21-7767 Drug Info IC50 = 955 nM [1]
FLUMEZAPINE Drug Info IC50 = 20 nM [2]
SB-271046 Drug Info Ki = 120 nM [3]
FLUTROLINE Drug Info IC50 = 14 nM [4]
Phenyltoloxamine Drug Info Ki = 343 nM [5]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [6]
1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine Drug Info Ki = 7600 nM [7]
(R)-2,11-Diaminoaporphine Drug Info Ki = 2920 nM [8]
(R)-11-Amino-2-methoxyaporphine Drug Info Ki = 78 nM [8]
FALCARINDIOL Drug Info Ki = 192 nM [9]
1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol Drug Info Ki = 5.4 nM [10]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine Drug Info IC50 = 1500 nM [11]
3-bromoboldine Drug Info IC50 = 66 nM [12]
NORSTEPHALAGINE Drug Info IC50 = 4800 nM [13]
1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol Drug Info Ki = 3700 nM [13]
3-Iodoboldine Drug Info IC50 = 3 nM [12]
6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol Drug Info Ki = 1940 nM [14]
9-Aminomethyl-9H-fluorene-3,4-diol Drug Info Ki = 380 nM [14]
11-Hexanoyloxy-N-n-propylnoraporphine Drug Info Ki = 10 nM [15]
(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine Drug Info Ki = 130 nM [16]
(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine Drug Info Ki = 1690 nM [16]
1-Aminomethyl-isochroman-5,6-diol Drug Info Ki = 1030 nM [17]
A-70108 Drug Info Ki = 1.6 nM [17]
PUKATEINE Drug Info IC50 = 400 nM [13]
N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide Drug Info Ki = 6800 nM [18]
6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol Drug Info Ki = 1650 nM [14]
(R)-(-)-2-methoxy-11-hydroxyaporphine Drug Info Ki = 46 nM [16]
R-N-PROPYLNORAPOMORPHINE Drug Info Ki = 3410 nM [16]
BOLDINE Drug Info IC50 = 400 nM [12]
BP-897 Drug Info Ki = 636 nM [19]
Ecopipam Drug Info Ki = 1.9 nM [20]
(+/-)-nantenine Drug Info Ki = 895 nM [21]
(+)-BUTACLAMOL Drug Info Ki = 1.8 nM [22]
MELOSMINE Drug Info IC50 = 12500 nM [13]
1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine Drug Info Ki = 379 nM [5]
6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol Drug Info Ki = 1740 nM [14]
MCL-516 Drug Info Ki = 1480 nM [23]
9-Aminomethyl-9H-fluorene-2,5,6-triol Drug Info Ki = 43 nM [14]
SCH-24518 Drug Info Ki = 2.35 nM [24]
IBZM Drug Info Ki = 12000 nM [25]
(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride Drug Info IC50 = 5640 nM
SCH-12679 Drug Info IC50 = 491 nM [26]
(S,S)-oxandrine hydrochloride Drug Info IC50 = 11100 nM
ISOLOXAPINE Drug Info IC50 = 2480 nM [27]
TEPA (possesses cytotoxic activity) Drug Info IC50 = 430 nM [28]
(R)-(-)-10-methyl-11-hydroxyaporphine Drug Info Ki = 9650 nM [29]
6-(2-Amino-ethyl)-biphenyl-2,3-diol Drug Info Ki = 1500 nM [14]
Fenoldopam Drug Info Ki = 15.0 nM [30]
(S)APOMORPHINE Drug Info Ki = 2980 nM [31]
2-methoxyapomorphine Drug Info Ki = 2600 nM [32]
(R)-(-)-2-methoxy-N-npropylnorapomorphine Drug Info Ki = 6450 nM [16]
(R)-(-)-11-hydroxy-N-n-propylnoraporphine Drug Info Ki = 699 nM [16]
1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine Drug Info Ki = 11000 nM [33]
1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane Drug Info Ki = 5200 nM [32]
2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol Drug Info Ki = 7600 nM [32]
(+)-(1R,1'S)-berbamunine hydrochloride Drug Info IC50 = 1040 nM
N-(4-Propylaminobutyl)-4-biphenylcarboxamide Drug Info Ki = 7300 nM [18]
QUINPIROLE Drug Info Ki = 63 nM [34]
4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine Drug Info Ki = 201 nM [5]
1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine Drug Info Ki = 10000 nM [33]
(R)-(+)-coclaurine Drug Info IC50 = 240 nM [35]
3,8-dibromoboldine Drug Info IC50 = 206 nM [12]
1-Aminomethyl-3-phenyl-isochroman-5,6-diol Drug Info Ki = 7200 nM [17]
(S)-BULBOCAPNINE Drug Info IC50 = 740 nM [13]
GLAUCINE Drug Info Ki = 2900 nM [13]
1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol Drug Info Ki = 10800 nM [13]
3-Chloroboldine Drug Info IC50 = 81 nM [12]
[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether Drug Info Ki = 5300 nM [32]
2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline Drug Info IC50 = 27 nM [36]
Pergolide Drug Info EC50 = 1040 nM [37]
ISOCLOZAPINE Drug Info IC50 = 11 nM [38]
11-Butyryloxy-N-n-propylnoraporphine Drug Info Ki = 12 nM [15]
11-Heptanoyloxy-N-n-propylnoraporphine Drug Info Ki = 31 nM [15]
11-valeryloxynoraporphine Drug Info Ki = 23 nM [15]
11-Propionyloxy-N-n-propylnoraporphine Drug Info Ki = 18 nM [15]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine Drug Info Ki = 113 nM [5]
STEPHOLIDINE Drug Info Ki = 5.9 nM [39]
1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine Drug Info Ki = 33.7 nM [5]
Etoloxamine Drug Info Ki = 1959 nM [5]
1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine Drug Info Ki = 14000 nM [33]
SK&F-89626 Drug Info IC50 = 120 nM [40]
(+)-(1R,1'S)-thaligrisine hydrochloride Drug Info IC50 = 5600 nM
Action against Disease Model Fenoldopam EC50 in relaxation of preconstricted mesenteric/l uMbar/renal artery: 3600nM/6200nM/3400nM [41] Drug Info
Methylergonovine The h uMan histamine H1 receptor (H1R) is an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are known to potently antagonize the H1R, thereby producing some of their side effects. In contrast, the tolerability and potential therapeutic utility of H1R agonism is currently unclear. We have used a cell-based functional assay to evaluate known therapeutics and reference drugs for H1R agonist activity. Our initial functional screen identified three ergot-based compounds possessing heretofore-unknown H1R agonist activity. 8R-lisuride demonstrated potent agonist activity in various assays including receptor selection and amplification technology, inositol phosphate acc uMulation, and activation of nuclear factor-kappaB with pEC50 values of 8.1, 7.9, and 7.9, respectively, and with varying degrees of efficacy. Based on these assays, 8R-lisuride is the most potent stereospecific partial agonist for the h uMan H1R yet reported. Investigation of the residues involved in histamine and lisuride binding, using H1R mutants and molecular modeling, have revealed that although these ligands are structurally different, the lisuride-binding pocket in the H1R closely corresponds to the histamine-binding pocket. The discovery of a potent stereospecific partial H1R agonist provides a valuable tool to further characterize this important therapeutic target in vitro. [42] Drug Info
References
REF 1J Med Chem. 1995 Jan 20;38(2):318-27.Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
REF 2J Med Chem. 1982 Oct;25(10):1133-40.Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems.
REF 3Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
REF 4J Med Chem. 1980 Jun;23(6):635-43.Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines.
REF 5J Med Chem. 2004 Aug 12;47(17):4155-8.Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity.
REF 6J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
REF 7Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. Epub 2006 Mar 24.Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype.
REF 8Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. Epub 2008 Jun 5.Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.
REF 9Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors.
REF 10J Med Chem. 1991 Oct;34(10):2946-53.Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.
REF 11J Med Chem. 1982 Jul;25(7):855-8.Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain.
REF 12J Nat Prod. 2000 Apr;63(4):480-4.Halogenated boldine derivatives with enhanced monoamine receptor selectivity.
REF 13J Med Chem. 2007 Jan 25;50(2):171-81.Advances in development of dopaminergic aporphinoids.
REF 14J Med Chem. 1986 Oct;29(10):1904-12.Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes.
REF 15Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. Epub 2008 Aug 28.N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.
REF 16J Med Chem. 2008 Feb 28;51(4):983-7. Epub 2008 Feb 6.Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.
REF 17J Med Chem. 1990 Nov;33(11):2948-50.(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.
REF 18J Med Chem. 2008 Nov 13;51(21):6829-38. Epub 2008 Oct 4.Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies.
REF 19Bioorg Med Chem Lett. 2004 Dec 6;14(23):5813-6.Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
REF 20J Med Chem. 1989 Aug;32(8):1913-21.Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1H-3-benzazepin-7-ol.
REF 21Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
REF 22J Med Chem. 2000 May 18;43(10):2079-81.7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists.
REF 23Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. Epub 2008 Nov 13.Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines.
REF 24J Med Chem. 1988 Oct;31(10):1941-6.Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands.
REF 25Bioorg Med Chem. 2007 Nov 1;15(21):6819-29. Epub 2007 Aug 19.In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors.
REF 26J Med Chem. 1998 Nov 5;41(23):4486-91.Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
REF 27J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain.
REF 28J Med Chem. 1998 Oct 8;41(21):4165-70.N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies.
REF 29Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. Epub 2007 May 23.R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands.
REF 30Dopamine D5 receptors: a challenge to medicinal chemists. Mini Rev Med Chem. 2008 Sep;8(10):976-95.
REF 31J Med Chem. 1990 Jun;33(6):1800-5.Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues.
REF 32Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. Epub 2008 Feb 15.Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines.
REF 33Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands.
REF 34J Med Chem. 2005 Sep 8;48(18):5771-9.Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
REF 35J Nat Prod. 1998 Jun 26;61(6):709-12.Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine.
REF 36J Med Chem. 1981 Sep;24(9):1107-10.Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists.
REF 37D1 dopamine receptor activity of anti-parkinsonian drugs. Life Sci. 1997;60(18):1597-603.
REF 38J Med Chem. 1997 Dec 5;40(25):4146-53.Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.
REF 39Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. Epub 2009 Aug 20.Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?.
REF 40J Med Chem. 1990 Jun;33(6):1756-64.trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
REF 41The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol. 1986 Nov;22(5):535-40.
REF 428R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol Pharmacol. 2004 Mar;65(3):538-49.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.